Several studies have demonstrated that the vitiligo disease activity and prognosis of cancer immunotherapy for melanoma correlate with the number and effector function of MSA-specific CD8+ T cells in the skin and melanoma, respectively (4–7). This evidence concerns the gene CD8A and cancer.